



Nath Bio-Genes (I) Ltd.
(CIN L01110MH1993PLC072842)

6th April, 2018

To,
The Assistant Vice President (Surveillance)
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G-Block, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051

Ref: NSE/CM/Surveillance/7374 dated 05.04.2018
Sub: Increase in Volume

Dear Sir,

This is with reference to the above referred letter we would like to submit that:

With regard to your contention that as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, all listed companies are required to intimate to Exchange all the events, information etc.


In this regard we submit herewith that being a listed company, our company is regular in providing all the required information/intimation in time as and when any event takes place that has a bearing on the operation/performance of the company.

Our company also ensures that investors have latest relevant information about our company on regular and timely basis. However, we also draw your attention to various notifications/information uploaded on the Exchanges for information to the investor community such as explanation about the sample survey of certain cotton seeds, Buyback of Equity Shares from Asset Reconstruction Company India Ltd., Investors meet, Investor Presentation of company and the further the Company has also raised funds through Qualified Institutional Placement (QIP) on 30.01.2018 and all the relevant information also provided to the stock exchanges on time to time.

We would ensure that in future also all the price sensitive information would be communicated to the investors.

We hope that the above information would be satisfactory information to your contention. Kindly confirm the receipt and do the needful.

For Nath Bio-Genes (India) Ltd.


Authorised Signatory